BeOne Medicines (ONC) Non-Current Deferred Tax Liability (2016 - 2026)

BeOne Medicines (ONC) has 11 years of Non-Current Deferred Tax Liability data on file, last reported at $55.9 million in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability rose 29.59% year-over-year to $55.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.9 million (up 29.59% YoY) and the FY2025 annual result came in at $53.2 million, up 26.67% from the prior year.
• Non-Current Deferred Tax Liability improved to $55.9 million in Q1 2026 per ONC's latest filing, from $53.2 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $55.9 million in Q1 2026 and bottomed at $14.2 million in Q1 2022.
• The 5-year median for Non-Current Deferred Tax Liability is $16.4 million (2024), against an average of $27.7 million.
• The widest annual swing landed in 2023, when Non-Current Deferred Tax Liability retreated 18.18%; it then soared 195.36% in 2025.
• Tracing ONC's Non-Current Deferred Tax Liability over 5 years: stood at $24.6 million in 2022, then decreased by 18.18% to $20.1 million in 2023, then surged by 108.9% to $42.0 million in 2024, then gained by 26.67% to $53.2 million in 2025, then climbed by 4.99% to $55.9 million in 2026.
• Per Business Quant, the three latest ONC Non-Current Deferred Tax Liability figures stand at $55.9 million (Q1 2026), $53.2 million (Q4 2025), and $47.1 million (Q3 2025).

Peer Comparison